Prognostic Profile of Dupuytren's Disease: a Cohort Study (PRODUCT)

计划入组 305 人 · 首次发布于 2026 年 1 月 20 日

Ultrasound Features of Dupuytren's Disease

计划入组 20 人 · 首次发布于 2025 年 5 月 2 日

Dupuytren's Disease and Extracorporeal Shockwave Therapy (DupuyShock-2010)

计划入组 60 人 · 首次发布于 2010 年 8 月 19 日

liver disease program

siRNA therapeutics for ocular disease/dermatological disease (Phio Pharmaceuticals)

undisclosed drug (fibrotic liver disease/NASH), Engitix/Takeda

Rare Disease Research, LLC

CASTLEMAN DISEASE COLLABORATIVE NETWORK

United States

CURE RARE DISEASE, INC.

United States

Ventoux Biosciences Secures U.S. Patent for Novel Dupuytren's Disease Treatment Approach

Connext Completes Enrollment in Phase 2 Trial of CNT201 for Dupuytren's Contracture

Xiaflex Meets Phase III Primary Endpoint in Plantar Fibromatosis, Setting Stage for First-Ever FDA Approval